A variety of nucleic acid amplification techniques have been integrated into different detection methods to promote the development of sensitive and convenient analysis of nucleic acids. However, it is still in urgent need to develop amplified nucleic acid biosensors for the analysis of susceptible gene and even distinguishing single-base mismatched DNA in complex biological samples. Benefiting from the achieved detection strategies, here we boost isothermal nucleic acid amplification by resorting to enzyme amplification, and combine this two-stage amplification method with surface-enhanced Raman spectroscopy (SERS) to develop a signal-on nucleic acid detection platform. Due to the high cleavage efficiency of Exonuclease III (Exo III), a large amount of trigger DNA are produced to initiate multiple hybridization chain reaction circles. The product structure tagged with Tamra is then anchored onto the plasmonic SERS substrate and meanwhile enriched. It is demonstrated that this detection platform is sensitive toward the myocardial infarction disease related gene. A detection limit of 1 fM for the gene analysis in a linear relationship in the wide range from 1 fM to 10 nM is achieved, better than most of previous counterparts. Meanwhile, our developed detection platform exhibits a high selectivity for the target gene over mismatched analogues. Our strategy provides a robust tool for signal amplification of gene detection even in blood samples.

各种核酸扩增技术已被集成到不同的检测方法中，以促进对核酸的灵敏且方便的分析的发展。然而，仍然迫切需要开发扩增的核酸生物传感器以分析易感基因，甚至在复杂的生物样品中区分单碱基错配的DNA。得益于已实现的检测策略，在这里，我们借助酶扩增来促进等温核酸扩增，并将这种两阶段扩增方法与表面增强拉曼光谱法（SERS）结合起来，以开发一种信号核酸检测平台。由于核酸外切酶III（Exo III）的高切割效率，产生了大量的触发DNA，以引发多个杂交链反应圈。然后将用Tamra标记的产物结构锚固在等离激元SERS底物上，同时进行富集。证明了该检测平台对心肌梗死疾病相关基因敏感。在从1 fM到10 nM的宽范围内的线性关系中，实现了1 fM的基因分析检测极限，优于大多数以前的同类产品。同时，我们开发的检测平台相对于错配的类似物对目标基因具有很高的选择性。我们的策略为即使在血液样本中的基因检测信号放大提供了一个强大的工具。在从1 fM到10 nM的宽范围内的线性关系中，对基因分析的检测极限为1 fM，优于大多数以前的同类产品。同时，我们开发的检测平台相对于错配的类似物对目标基因具有很高的选择性。我们的策略为即使在血液样本中的基因检测信号放大提供了一个强大的工具。在从1 fM到10 nM的宽范围内的线性关系中，实现了1 fM的基因分析检测极限，优于大多数以前的同类产品。同时，我们开发的检测平台相对于错配的类似物对目标基因具有很高的选择性。我们的策略为即使在血液样本中的基因检测信号放大提供了一个强大的工具。